Could a skin blister test lead to a treatment for 'Drowning from the Inside'?

NCT ID NCT05600062

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a drug called racecadotril can reduce fluid leakage in skin blisters, as a model for what happens in the lungs during Acute Respiratory Distress Syndrome (ARDS). ARDS is a severe lung injury with no effective drug treatments, where patients' lungs fill with fluid. The trial involves 48 healthy volunteers and uses a safe blister-inducing substance to measure whether the drug strengthens blood vessel barriers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Racecadotril (an oral capsule that blocks an enzyme called neutral endopeptidase)
What this could lead to
If this drug reduces fluid leak in the blister model, it could point toward a new treatment for ARDS, a severe lung condition with no current drug therapy.
What could go wrong
This is an early-stage study in healthy volunteers, not ARDS patients. The skin blister model may not fully reflect what happens in the lungs, and the drug may not work in real ARDS cases.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE RESPIRATORY DISTRESS SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • William Harvey Research Institute- Heart Centre

    London, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.